DFDA

Edaravone

Treatment for Motor Neuron Disease

Typical Dosage: 60 mg IV infusion daily for 14 days, followed by 14-day break; subsequent cycles 10 of 14 days, 14-day break (Oral suspension also available)

Effectiveness
55%
Safety Score
65%
Clinical Trials
11
Participants
600

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
60 mg IV infusion daily for 14 days, followed by 14-day break; subsequent cycles 10 of 14 days, 14-day break (Oral suspension also available)
Time to Effect
3-6 months
Treatment Duration
Lifetime (cycles)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$165,000
Monitoring:$7,500
Side Effect Mgmt:$500
Total Annual:$173,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$500,000/QALY
QALYs Gained
0.07
Comparison vs Riluzole + Best Supportive Care
Cost Difference
+$170,500/year
More expensive
QALY Difference
+0.07 QALYs
Better outcomes
Dominance
No dominance
Edaravone Outcomes

for Motor Neuron Disease

Efficacy Outcomes
Overall Effectiveness
+55%
Common Side Effects
Contusion
+9.6%
Gait disturbance
+8.4%
Headache
+7.2%
Infusion site reaction
+7%

Sources:

neurores.org
nih.gov
clinicalcasereportsint.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Edaravone in Motor Neuron Disease

Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone

NCT04097158RECRUITING
View Study
160 participants
OBSERVATIONAL
Loma Linda, United States
Started: Oct 8, 2019

FHND1002 for ALS Treatment: Phase 2

NCT07138014NOT YET RECRUITINGPHASE2
View Study
180 participants
INTERVENTIONAL
Started: Oct 1, 2025
Completed Clinical Trials
6 completed trials for Edaravone in Motor Neuron Disease

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT00330681COMPLETEDPHASE3
View Study
206 participants
INTERVENTIONAL
Started: May 1, 2006

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00424463COMPLETEDPHASE3
View Study
181 participants
INTERVENTIONAL
Watari-gun, Japan
Started: Jan 1, 2007

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

NCT00415519COMPLETEDPHASE3
View Study
25 participants
INTERVENTIONAL
Started: Dec 1, 2006

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

NCT01492686COMPLETEDPHASE3
View Study
137 participants
INTERVENTIONAL
Osaka, Japan
Started: Dec 1, 2011

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04577404COMPLETEDPHASE3
View Study
124 participants
INTERVENTIONAL
Phoenix, United States +43 more
Started: Oct 29, 2020

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

NCT05178810COMPLETEDPHASE3
View Study
313 participants
INTERVENTIONAL
Leuven, Belgium +37 more
Started: Oct 18, 2021